OCS Dividend: Oculis Holding AG Yield Insights

Q: What are Oculis Holding AG's key financial statements?

According to the latest financial statement (Form-10K), Oculis Holding AG has a total asset of $120, Net loss of $-85

Q: What are the key financial ratios for OCS?

Oculis Holding AG's Current ratio is 2.6, has a Net margin is 0, sales per share of $0.

Q: How is Oculis Holding AG's revenue broken down by segment or geography?

Currently Oculis Holding AG data is not available.

Q: Is Oculis Holding AG profitable?

no, according to the latest financial statements, Oculis Holding AG has a net loss of $-85

Q: Does Oculis Holding AG have any liabilities?

yes, Oculis Holding AG has liability of 46

Q: How many outstanding shares for Oculis Holding AG?

Oculis Holding AG has a total outstanding shares of 44.66

Home

Stock

OCS

OCS Financial

Oculis Holding AG

$25.22

5.78%

$1.37

At close: Jan 16, 16:00:00 GMT-5

$25.25

0.11%

$0.03

Post-market: Jan 16, 20:00:00 GMT-5

Overview Forecast Earnings Dividends Financials

Key Stats

Prev.Close

$23.84

Open

$23.82

Day's Range

$23.69 - $26.17

52 week range

$14 - $26.17

Volume

428.1K

Avg.Volume

133.1K

EPS (TTM)

-2.17

Dividend yield

Market Cap

$1.4B

What is OCS?

Oculis Holding AG is a global biopharmaceutical company, which engages in sight and improving eye care. The company is headquartered in Zug, Zug and currently employs 49 full-time employees. The company went IPO on 2023-03-03. The firm is focused on the development of eye disease treatment for ophthalmology. The company includes OCS-01, based on the OPTIREACH technology, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED) in a form of a single chain antibody fragment; and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and for other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The firm have operations in the USA, Europe and China. Ocullis deliver treatments to patients worldwide.



Features

AI Copilot for Stock & Crypto

Trading Strategies

Megabrain Investors Picks

Resources

Market

Income

Balance sheet

Cash flow

Annual

Quarterly

OCS Income

Financials in millions USD. Fiscal year is February - January.

Breakdown	TTM	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020
Revenue	0	0	0	0	0	0
Revenue Growth (YoY)	--	--	--	--	--	--
Cost of Revenue	44	47	29	19	6	6
Gross Profit	-44	-47	-29	-19	-6	-6
Selling, General & Admin	13	11	7	4	2	1
Research & Development	17	11	6	4	4	3
Operating Expenses	33	25	15	12	6	5
Other Non Operating Income (Expenses)	-22	-15	-3	--	--	0
Pretax Income	-104	-85	-88	-38	-18	-14
Income Tax Expense	0	0	0	0	0	0
Net Income	-104	-85	-88	-38	-18	-14
Net Income Growth	51%	-3%	132%	111%	28.99%	--
Shares Outstanding (Diluted)	52.36	40.4	29.89	32.73	32.73	32.73
Shares Change (YoY)	25%	35%	-9%	0%	0%	--
EPS (Diluted)	-1.98	-2.12	-2.97	-1.18	-0.57	-0.45
EPS Growth	19%	-28.99%	152%	107%	27%	--
Free Cash Flow	-61	-47	-53	-28	-13	-12
Free Cash Flow Per Share	--	--	--	--	--	--
Gross Margin	0%	0%	0%	0%	0%	0%
Operating Margin	0%	0%	0%	0%	0%	0%
Profit Margin	0%	0%	0%	0%	0%	0%
Free Cash Flow Margin	0%	0%	0%	0%	0%	0%
EBITDA	-78	-73	-45	-32	-13	-12
EBITDA Margin	0%	0%	0%	0%	0%	0%
D&A For EBITDA	0	0	0	0	0	0
EBIT	-78	-73	-45	-32	-13	-12
EBIT Margin	0%	0%	0%	0%	0%	0%
Effective Tax Rate	0%	0%	0%	0%	0%	0%

Follow-Up Questions

What are Oculis Holding AG's key financial statements?



What are the key financial ratios for OCS?



How is Oculis Holding AG's revenue broken down by segment or geography?



Is Oculis Holding AG profitable?



Does Oculis Holding AG have any liabilities?



How many outstanding shares for Oculis Holding AG?



Oculis Holding AG (OCS) Price

OCS Stock Price Chart